Cargando…

Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin

AIMS. Despite numerous recent advances in the management of patients with type 2 diabetes, there remains a paucity of data to guide sequential treatment intensification. METHODS. This was a single-center, retrospective cohort study of patients receiving metformin, basal insulin, and a sulfonylurea w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santeusanio, Andrew D., Bowen, Monica M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	Feature Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092894/ https://www.ncbi.nlm.nih.gov/pubmed/30140142 http://dx.doi.org/10.2337/ds17-0068

Ejemplares similares

Erratum: Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin. Diabetes Spectrum 2018;31:261–266 (doi.org/10.2337/ds17-0068)
por: Santeusanio, Andrew D., et al.
Publicado: (2018)

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy
por: Wright, Eugene E., et al.
Publicado: (2021)

Role of Noninsulin Therapies Alone or in Combination in Chromosome 6q24-Related Transient Neonatal Diabetes: Sulfonylurea Improves but Does Not Always Normalize Insulin Secretion
por: Carmody, David, et al.
Publicado: (2015)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

SAT-LB026 Basal-Prandial Insulin versus Basal-Sliding-Scale Insulin in the Management of Hyperglycemia in Non-Critically Ill Hospitalized Patients
por: Malkhasyan, Victoria, et al.
Publicado: (2019)

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023)

Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices
por: El-Laboudi, Ahmed H., et al.
Publicado: (2015)

BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin
por: Zisman, Ariel, et al.
Publicado: (2016)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Analysis of a Delivery Device Conversion for Insulin Aspart: Potential Clinical Impact in Veterans
por: Moorman Spangler, Caitlin M., et al.
Publicado: (2016)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

Advancing Patient Safety and Access to Concentrated Insulin (U-500 Regular Insulin) in the Veterans Health Administration: A Clinician Education Program in the Primary Care Setting
por: Lutz-McCain, Stacey J., et al.
Publicado: (2018)

Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
por: Hinnen, Debbie A.
Publicado: (2015)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
por: Bergenstal, R. M., et al.
Publicado: (2016)

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
por: Blevins, T., et al.
Publicado: (2016)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes
por: Edelman, Steven, et al.
Publicado: (2007)

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
por: Jain, S M, et al.
Publicado: (2010)

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2014)

Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
por: Goldman, Jennifer D., et al.
Publicado: (2023)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
por: Jones, Angus G, et al.
Publicado: (2012)

Association Between Change in A1C and Use of Professional Continuous Glucose Monitoring in Adults With Type 2 Diabetes on Noninsulin Therapies: A Real-World Evidence Study
por: Nemlekar, Poorva M., et al.
Publicado: (2023)

Optimal prandial timing of bolus insulin in diabetes management: a review
por: Slattery, D., et al.
Publicado: (2017)

Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
por: Wysham, Carol H., et al.
Publicado: (2018)

Sulfonylureas: Scoring beyond START STUDY
por: Shaikh, Altamash
Publicado: (2017)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study
por: Jin, Yujing, et al.
Publicado: (2017)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
por: Tinahones, F J, et al.
Publicado: (2014)

Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods
por: Chow, Nelson, et al.
Publicado: (2016)

The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy
por: Ozturkmen, Yuksel Asli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lrgosicuq8ru0q1r30cv8t91b